821 ALK expression in metastatic cutaneous squamous cell carcinoma: A pilot study

Abstract

Background: Cutaneous squamous cell carcinoma (SCC) is a common skin cancer, with over 1,000,000 cases and up to 9,000 deaths annually in the United States. Treatment options for metastatic SCC are limited, although inhibitors of PD-1 and EGFR have shown some success clinically. Our group identified ALK as a potential driver mutation in metastatic SCC through targeted sequencing. Here, we examine the role of ALK overexpression in SCC. Methods: All metastatic SCCs at our institution from 2010-2018 with tissue available were included, which yielded fifteen primary SCCs and fifteen patient-matched lymph node metastases.